{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:35:53Z","timestamp":1793090153387,"version":"4.5.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105540","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:16:00Z","timestamp":1786464960000},"page":"105540","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mechanistic insights into genomic basis of crosstalk between metabolic reprogramming and immune dysfunction in ovarian cancer"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-2061-3287","authenticated-orcid":false,"given":"Meghna","family":"Patial","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavindra Kumar","family":"Kesari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhruv","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105540_bib1","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.3390\/cancers14112640","article-title":"Pharmacologic induction of BRCAness in BRCA-proficient cancers: expanding PARP inhibitor use","volume":"14","author":"Abbotts","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105540_bib2","doi-asserted-by":"crossref","first-page":"650","DOI":"10.3390\/cells11040650","article-title":"Recent advances in ovarian cancer: therapeutic strategies, potential biomarkers, and technological improvements","volume":"11","author":"Akter","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105540_bib3","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.3390\/biomedicines10123089","article-title":"Succinate at the crossroad of metabolism and angiogenesis: roles of SDH, HIF1\u03b1 and SUCNR1","volume":"10","author":"Atallah","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.critrevonc.2026.105540_bib4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3390\/biology11020270","article-title":"Oncometabolites\u2014a link between cancer cells and tumor microenvironment","volume":"11","author":"Bary\u0142a","year":"2022","journal-title":"Biol."},{"key":"10.1016\/j.critrevonc.2026.105540_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1295257","article-title":"Tumor-associated macrophages: an effective player of the tumor microenvironment","author":"Basak","year":"2023","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105540_bib6","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin."},{"key":"10.1016\/j.critrevonc.2026.105540_bib7","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian Cancer","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.critrevonc.2026.105540_bib8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/BCTT.S383759","article-title":"Chromosomal Instability as Enabling Feature and Central Hallmark of Breast Cancer","volume":"15","author":"Castellanos","year":"2023","journal-title":"Breast Cancer Targets Therapy"},{"key":"10.1016\/j.critrevonc.2026.105540_bib9","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.3390\/biom13081253","article-title":"Endometriosis-Associated Ovarian Carcinomas: How PI3K\/AKT\/mTOR Pathway Affects Their Pathogenesis","volume":"13","author":"Driva","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.critrevonc.2026.105540_bib10","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1111\/bph.70110","article-title":"Role of monocarboxylate transporters in cancer immunology and their therapeutic potential","volume":"182","author":"Faghihkhorasani","year":"2025","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105540_bib11","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-025-01917-7","article-title":"Global burden of ovarian cancer attributable to high BMI, 1990\u20132021: spatiotemporal trends, risk factors, frontier analysis, and projections to 2036 based on GBD 2021 study","author":"He","year":"2025","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.critrevonc.2026.105540_bib12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12672-023-00793-1","article-title":"Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer","volume":"14","author":"He","year":"2023","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105540_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1175563","article-title":"Association between pH regulation of the tumor microenvironment and immunological state","volume":"13","author":"Hosonuma","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105540_bib14","article-title":"Function of reactive oxygen species in myeloid-derived suppressor cells","author":"Huang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105540_bib15","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11033-024-10049-y","article-title":"Decoding PTEN: from biological functions to signaling pathways in tumors","volume":"51","author":"Huang","year":"2024","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.critrevonc.2026.105540_bib16","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1007\/s12015-025-10956-y","article-title":"Metabolic Plasticity and Cancer Stem Cell Metabolism: Exploring the Glycolysis-OXPHOS Switch as a Mechanism for Resistance and Tumorigenesis","volume":"21","author":"Keoh","year":"2025","journal-title":"Stem Cell. Rev. Rep."},{"key":"10.1016\/j.critrevonc.2026.105540_bib17","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41416-024-02776-7","article-title":"PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers","volume":"131","author":"Kristeleit","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105540_bib18","article-title":"Glutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases","volume":"6","author":"Kumar","year":"2025","journal-title":"MedComm (Beijing)"},{"key":"10.1016\/j.critrevonc.2026.105540_bib19","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/s41418-024-01402-6","article-title":"Oncometabolites at the crossroads of genetic, epigenetic and ecological alterations in cancer","volume":"31","author":"Lanzetti","year":"2024","journal-title":"Cell. Death Differ."},{"key":"10.1016\/j.critrevonc.2026.105540_bib20","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3390\/ijms27031617","article-title":"High-Grade Serous Ovarian Carcinoma in the Genomics Era: Current Applications, Challenges and Future Directions","volume":"27","author":"Lewis","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105540_bib21","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12964-023-01449-x","article-title":"Glutamine addiction in tumor cell: oncogene regulation and clinical treatment","volume":"22","author":"Li","year":"2024","journal-title":"Cell. Commun. Signal."},{"key":"10.1016\/j.critrevonc.2026.105540_bib22","article-title":"Omentum provides a special cell microenvironment for ovarian cancer","volume":"6","author":"Li","year":"2023","journal-title":"Cancer Rep."},{"key":"10.1016\/j.critrevonc.2026.105540_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1030831","article-title":"Metabolic reprogramming of the tumor immune microenvironment in ovarian cancer: A novel orientation for immunotherapy","volume":"13","author":"Lin","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105540_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/adbi.202400720","article-title":"Research Progress on the Combination of PARP Inhibitors (PARPi) and Immune Checkpoint Inhibitors (ICIs)","volume":"9","author":"Liu","year":"2025","journal-title":"Adv. Biol."},{"key":"10.1016\/j.critrevonc.2026.105540_bib25","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2147\/CMAR.S421771","article-title":"Role of Human Monocarboxylate Transporter 1 (hMCT1) and 4 (hMCT4) in Tumor Cells and the Tumor Microenvironment","volume":"15","author":"Liu","year":"2023","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.critrevonc.2026.105540_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102647","article-title":"Hyperoxia induces glucose metabolism reprogramming and intracellular acidification by suppressing MYC\/MCT1 axis in lung cancer","volume":"61","author":"Liu","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.critrevonc.2026.105540_bib27","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.3390\/cells11162518","article-title":"An Epigenetic Role of Mitochondria in Cancer","volume":"11","author":"Liu","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105540_bib28","article-title":"To cleave or not and how? The DNA exonucleases and endonucleases in immunity","volume":"12","author":"Lu","year":"2025","journal-title":"Genes. Dis."},{"key":"10.1016\/j.critrevonc.2026.105540_bib29","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.3390\/ijms25063313","article-title":"A Molecular Perspective on HIF-1\u03b1 and Angiogenic Stimulator Networks and Their Role in Solid Tumors: An Update","volume":"25","author":"Magar","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105540_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.880643","article-title":"Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors","volume":"12","author":"Mekonnen","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105540_bib31","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3390\/metabo13040560","article-title":"Deregulated Metabolic Pathways in Ovarian Cancer: Cause and Consequence","volume":"13","author":"Murali","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.critrevonc.2026.105540_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cells13040345","article-title":"Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer\u2014Genetic Instability and Clinical Implications","author":"Murawski","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.critrevonc.2026.105540_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1548234","article-title":"Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies","volume":"16","author":"Nair","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105540_bib34","first-page":"13","article-title":"Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer","author":"Ni","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105540_bib35","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41416-023-02263-5","article-title":"Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2","volume":"128","author":"O\u2019Mahony","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105540_bib36","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13046-025-03355-1","article-title":"CircPVT1 weakens miR-33a-5p unleashing the c-MYC\/GLS1 metabolic axis in breast cancer","volume":"44","author":"Palcau","year":"2025","journal-title":"J. Exp. & Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105540_bib37","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1111\/febs.16086","article-title":"Indoleamine 2,3-dioxygenase 1 (IDO1): an up-to-date overview of an eclectic immunoregulatory enzyme","volume":"289","author":"Pallotta","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.critrevonc.2026.105540_bib38","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.5858\/arpa.2022-0166-RA","article-title":"Recent advances in the classification of gynecological tract tumors: updates from the 5th Edition of the World Health Organization \u201cBlue Book","volume":"147","author":"Parkash","year":"2023","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.critrevonc.2026.105540_bib39","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.3390\/cancers13143465","article-title":"Mutated p53 in HGSC\u2014From a Common Mutation to a Target for Therapy","volume":"13","author":"Saleh","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2026.105540_bib40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41416-022-01797-4","article-title":"The STING pathway: Therapeutic vulnerabilities in ovarian cancer","volume":"127","author":"Shakfa","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105540_bib41","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.3390\/ijms26104611","article-title":"Ovarian cancer\u2014epidemiology, classification, pathogenesis, treatment, and estrogen receptors\u2019 molecular backgrounds","volume":"26","author":"Smolarz","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105540_bib42","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.3390\/cancers15112895","article-title":"Interactions of IDO and the kynurenine pathway with cell transduction systems and metabolism at the inflammation\u2013cancer interface","volume":"15","author":"Stone","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105540_bib43","article-title":"Therapeutic implications of FABP4 in cancer: an emerging target to tackle cancer","author":"Sun","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.critrevonc.2026.105540_bib44","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.7150\/thno.105276","article-title":"Metabolic regulation of myeloid-derived suppressor cells in tumor immune microenvironment: targets and therapeutic strategies","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.critrevonc.2026.105540_bib45","doi-asserted-by":"crossref","first-page":"5837","DOI":"10.3390\/ijms23105837","article-title":"PD-1\/PD-L1, MDSC pathways, and checkpoint inhibitor therapy in Ph(-) myeloproliferative neoplasm: a review","volume":"23","author":"Wang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105540_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202250182","article-title":"Combination therapy of HIF\u03b1 inhibitors and Treg depletion strengthen the anti-tumor immunity in mice","volume":"53","author":"Wei","year":"2023","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105540_bib47","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s42764-022-00087-w","article-title":"Exploring the DNA damage response pathway for synthetic lethality","volume":"4","author":"Xu","year":"2022","journal-title":"Genome Instab. Dis."},{"key":"10.1016\/j.critrevonc.2026.105540_bib48","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13046-025-03377-9","article-title":"Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy","volume":"44","author":"Yang","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105540_bib49","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/s41423-023-01013-0","article-title":"The chemokine monocyte chemoattractant protein-1\/CCL2 is a promoter of breast cancer metastasis","volume":"20","author":"Yoshimura","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.critrevonc.2026.105540_bib50","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/15384101.2022.2109899","article-title":"The cGAS\/STING signaling pathway: a cross-talk of infection, senescence and tumors","volume":"22","author":"Zeng","year":"2023","journal-title":"Cell. Cycle"},{"key":"10.1016\/j.critrevonc.2026.105540_bib51","article-title":"Targeting SREBP-1-mediated lipogenesis as potential strategies for cancer","volume":"12","author":"Zhao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105540_bib52","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.7150\/ijbs.99680","article-title":"A new perspective on the therapeutic potential of tumor metastasis: targeting the metabolic interactions between TAMs and tumor cells","volume":"20","author":"Zhao","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105540_bib53","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s43556-024-00176-0","article-title":"Understanding PI3K\/Akt\/mTOR signaling in squamous cell carcinoma: mutated PIK3CA as an example","volume":"5","author":"Zheng","year":"2024","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.critrevonc.2026.105540_bib54","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13046-025-03430-7","article-title":"Targeting glutamine metabolism as a potential target for cancer treatment","volume":"44","author":"Zou","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826004270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:51:22Z","timestamp":1793087482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826004270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":54,"alternative-id":["S1040842826004270"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105540","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic insights into genomic basis of crosstalk between metabolic reprogramming and immune dysfunction in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105540","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105540"}}